PP
LUMO

Paloma Partners’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Paloma Partners’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,367
Closed -$191K – 2349
2019
Q2 		$191K Buy
+14,367
New +$217K ﹤0.01% 1552
2019
Q1 		– Sell
-2,222
Closed -$30K – 2005
2018
Q4 		$30K Buy
+2,222
New +$39.1K ﹤0.01% 1184

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paloma Partners's LUMO Position: Q3 2019 in Review

Paloma Partners sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2019, closing a stake of 14,367 shares — an estimated $191K sold.

Paloma Partners first reported a position in LUMO in Q4 2018 and held it in 2 quarters. The position peaked at $191K in Q2 2019. 68 funds tracked by Wall St. Rank hold LUMO as of Q3 2019.

  • Paloma Partners reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 14,367 Lumos Pharma, Inc. Common Stock shares in Q3 2019, an estimated $191K.
  • Paloma Partners first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Paloma Partners's Lumos Pharma, Inc. Common Stock position peaked at $191K in Q2 2019.
  • 68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.